10-Q: FONAR Corporation Reports Q3 2026 Results Amidst Going-Private Deal

FONAR Corporation's Q3 2026 Form 10-Q reveals a slight revenue increase but a decrease in net income, alongside ongoing progress in a proposed going-private transaction.

Summary

• FONAR Corporation reported net income of $7.5 million on revenues of $78.1 million for the nine months ended March 31, 2026, a decrease from $9.3 million in net income on $77.1 million in revenues for the same period in the prior year.
• For the three months ended March 31, 2026, net income was $2.3 million on revenues of $26.5 million, down from $3.1 million on $27.2 million in revenues for the same period in 2025.
• The company is progressing with a proposed going-private transaction initiated by its CEO, Timothy Damadian, with a special meeting of stockholders scheduled for May 28, 2026.
• Material weaknesses in internal controls over financial reporting, specifically related to IT general controls, are being addressed.
• The company's primary segments are the manufacturing and servicing of medical equipment and the management of diagnostic imaging centers (HMCA).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to declining net income and operating income, increased costs outpacing revenue growth, and ongoing risks related to industry pressures and the pending merger.

Positives

• Total revenues increased slightly by 1.3% to $78.1 million for the nine months ended March 31, 2026, compared to $77.1 million for the same period in 2025.
• Revenues from product sales and service/repair fees increased to $7.2 million for the first nine months of fiscal 2026 from $6.4 million in fiscal 2025.
• The number of scans performed by owned and managed sites increased to 165,612 in the first nine months of fiscal 2026 from 160,844 in the prior year.
• Working capital increased to $131.9 million at March 31, 2026, from $127.5 million at June 30, 2025.
• The company believes its existing cash, internal cash generation, and ability to secure additional financing are sufficient for at least the next 12 months.

Negatives

• Consolidated net income decreased to $7.5 million for the nine months ended March 31, 2026, from $9.3 million in the prior year.
• Operating income decreased to $8.6 million for the nine months ended March 31, 2026, from $10.7 million in the prior year.
• Patient fee revenue decreased by approximately $1.3 million for the nine months ended March 31, 2026, compared to the prior year.
• Costs and expenses increased by 4.5% to $69.4 million for the first nine months of fiscal 2026, outpacing the 1.3% revenue increase.
• The company identified material weaknesses in its internal controls over financial reporting related to IT general controls.

Risks

• Proposed New York tort reform measures could impact the automotive insurance industry and potentially affect the company.
• Reduced reimbursement rates from Medicare, government programs, and private insurers continue to pressure profitability, especially in the scanning center business.
• Inflation has significantly increased costs for materials and labor, making organic growth and new center profitability more challenging.
• Cybersecurity threats pose a significant risk, with potential for operational disruption, data breaches, and substantial response costs, despite ongoing remediation efforts for identified control weaknesses.
• Dependence on referrals from physicians and third parties for scanning services means a reduction in referrals could significantly decrease scan volumes and revenue.
• Changes in Florida insurance law, particularly the Tort Reform Act and potential repeal of no-fault insurance, could lead to payment delays and negatively impact operations.
• Intense competition in the diagnostic imaging market, especially in Florida, coupled with reform measures, creates a challenging landscape.
• Pressure to control healthcare costs from managed care organizations could negatively impact utilization and pricing of services.
• Changes in eligibility for insurance programs, including government programs like Medicaid, could shift the payor mix towards lower reimbursement rates or increase uncollectible receivables.
• Non-compliance with federal and state privacy and information security laws (e.g., HIPAA) could materially harm the business.
• Reduced reimbursement rates negatively affect MRI scanner sales, potentially impacting economies of scale and profit margins.
• Manufacturing competition from larger companies with greater resources poses a challenge, although FONAR holds a unique position with its Stand-Up MRI scanner.
• Adverse changes in general domestic and global economic conditions, including tariffs, recessions, or disruptions in credit markets, could negatively impact operations.
• The proposed going-private merger may not be completed, which could adversely affect the stock price and business operations.
• Stockholder litigation related to the proposed merger introduces uncertainty, potential costs, and diversion of management attention.

Future Outlook

The company expects to complete the going-private merger in its fourth fiscal quarter of 2026, subject to various closing conditions. Management plans to open an additional MRI location on Long Island, New York, with expected costs of approximately $400,000 for a new scanner and $500,000 for buildout. The company believes its capital resources are adequate to support operations for at least the next 12 months.

Management Comments

• The company attributes the increase in scans performed to additional marketing efforts, adopted operational efficiencies, and the absence of hurricane-related closures experienced in the prior year.
• Management notes that the decrease in patient fee revenue is attributable to increased competition in several Florida locations.
• The company is committed to improving operating results and dealing with challenges posed by legislative and regulatory requirements.
• Management believes its business plan has been responsible for its profitability in the past ten consecutive fiscal years and the first nine months of fiscal 2026.

Industry Context

StockSavvy.ai notes that FONAR's results reflect broader industry pressures, including declining reimbursement rates for MRI scans and increasing operational costs due to inflation. The proposed going-private transaction, led by the CEO, suggests a strategic shift away from public market scrutiny, potentially to navigate these industry challenges more effectively or to consolidate ownership.

Comparison to Industry Standards

• The company's net income margin for the nine months ended March 31, 2026, was approximately 9.6% ($7.5M / $78.1M), which is lower than the typical profitability seen in stable healthcare service providers, potentially due to increased costs and competitive pressures.
• The increase in costs and expenses (4.5%) outpacing revenue growth (1.3%) for the nine-month period is a concern, indicating potential margin compression, a trend observed in parts of the healthcare services sector facing reimbursement pressures.
• The company's reliance on Medicare and managed care reimbursement rates, which are largely dictated by Medicare's flat rates for 2026, aligns with industry-wide challenges where operational costs like technologist and radiologist compensation are rising faster than reimbursement.
• The cybersecurity risks highlighted are a pervasive concern across the healthcare industry, with many organizations facing similar threats and investing heavily in IT security.

Corporate Governance

Legal Proceedings

• A Verified Stockholder Class Action Complaint was filed alleging that the proposed merger is subject to Section 203 of the Delaware General Corporation Law's supermajority voting requirement, which the company disputes.
• The company is subject to other legal proceedings and claims arising in the ordinary course of business, which management believes will not have a material adverse effect.

Related Party Transactions

• Management and other fees receivable from related medical practices totaled $10,042 thousand as of March 31, 2026.
• Service and repair fees of $135 thousand were recorded from Bensonhurst MRI Limited Partnership (in which the CEO holds an interest) for the nine months ended March 31, 2026.
• Reimbursable salaries and marketing expenses of $513 thousand were charged to Bensonhurst MRI Limited Partnership for the nine months ended March 31, 2026.
• Radian Healthcare Management, LLC (owned by the CEO's son-in-law) provided personnel recruitment services for fees of approximately $125 thousand for the nine months ended March 31, 2026.
• The Company recorded investment income of $36 thousand on a promissory note from Magnetic Resonance Management, LLC (owned by the CEO) for the sale of an MRI scanner for the nine months ended March 31, 2026.

Stakeholder Impact

• Shareholders: The proposed going-private transaction offers cash consideration ($19.00 for Common Stock, $6.34 for Class C, $10.50 for Class A Preferred), but they will no longer participate in future upside. Stockholder litigation is ongoing.
• Employees: Uncertainty surrounding the merger may affect employee morale and retention. Key personnel may be retained post-merger.
• Customers: Potential disruption to business relationships due to merger uncertainty. The company aims to preserve goodwill.
• Creditors: No specific impact mentioned, but overall financial health and liquidity are key considerations.

Next Steps

• Hold a special meeting of stockholders on May 28, 2026, to vote on the proposed Merger Agreement.
• Complete the going-private transaction, expected in the fourth fiscal quarter of 2026.
• Open an additional MRI location on Long Island, New York.

Key Dates

Recommendation

The company shows declining profitability and faces significant industry headwinds (reimbursement pressure, inflation) and operational risks (cybersecurity, internal controls). While the going-private transaction offers a cash exit for shareholders, the delay and ongoing litigation create uncertainty. The current financial performance does not warrant a buy, and the potential for further downside if the merger fails or industry conditions worsen suggests holding rather than selling.

Keywords

FONAR Corporation, Form 10-Q, Quarterly Report, MRI, Medical Equipment, Diagnostic Imaging, HMCA, Going Private Transaction, Merger Agreement, Financial Results, Healthcare Industry, Reimbursement Rates, Cybersecurity